RNS Number:6071C
VASTox plc
09 May 2006

                                   VASTox plc
                          ("VASTox" or "the Company")

                      VASTOX APPOINTS DARREN MILLINGTON AS
                      CHIEF FINANCIAL OFFICER AND DIRECTOR


Oxford, UK, 9 May 2006 - VASTox (AIM: VOX), a leading chemical genomics company,
today announces that Darren Millington ACMA, formerly VASTox' Head of Finance,
has joined the Board of Directors as Chief Financial Officer. He will continue
in his role as Company Secretary.


Mr Millington (30) joined VASTox in April 2005 and has been instrumental in
helping the business establish and build support functions alongside VASTox's
scientific and commercial successes.


Mr Millington is a Chartered Management Accountant. Having worked in the Audit
and Advisory Divisions at Arthur Andersen and later at Deloitte & Touche, he
joined IP2IPO plc as Group Financial Controller in 2003. During his time at
IP2IPO he gained valuable experience in a broad range of corporate finance
activities, as well as being responsible for the management of the accounts
function.


At the date of this announcement, Mr Millington holds options over 150,000
ordinary shares of 1p each in the capital of the Company ("Ordinary Shares"),
which were granted prior to his appointment as Chief Financial Officer with
exercise prices equal to the market value of an Ordinary Share on the date of
grant. Mr Millington also holds 1,111 Ordinary Shares at the date of his
appointment.


Mr Millington currently has no other directorships and has not been a director
of a company within the preceding five years.


Steven Lee, PhD, CEO of VASTox said: "I am pleased to announce Darren's
appointment to the Board of VASTox. He has made a significant contribution
across a number of areas in the business over the past year. Together with the
recent announcement of Richard Storer as Chief Scientific Officer, we are
building a high calibre Executive team to accelerate value growth."


VASTox plc confirms that, save for the above; there are no other matters under
paragraph (g) of Schedule 2 of the AIM rules to be announced.


                                    - ends -


For more information please contact:


VASTox

Steven Lee, PhD, Chief Executive Officer                 Tel: +44 (0)1235 443910

Darren Millington, Chief Financial Officer


Citigate Dewe Rogerson

David Dible / Mark Swallow / Valerie Auffray            Tel: +44 (0)207 638 9571


About VASTox plc


VASTox is a chemical genomics technology company that discovers and develops
proprietary novel drugs and provides services to the pharmaceutical industry.
The company's most advanced drug development programme is focused on developing
a new treatment for Duchenne Muscular Dystrophy based on the up-regulation of
utrophin. A second drug development programme for Spinal Muscular Atrophy is
also progressing rapidly. VASTox has two additional programmes focused on
osteoarthritis and tuberculosis that are expected to be out-licensed prior to
entering the clinic.


The company's technology platform, which uses zebrafish and fruitflies, has the
potential to dramatically decrease the time and cost of drug discovery and
development. This is because using whole organisms allows it to carry out high
volume, high content screening that delivers data which is highly predictive of
the efficacy and toxicity of potential drug compounds in humans. VASTox is
growing revenues based on marketing its unique technology platform and its
chemistry expertise.


VASTox was formed in January 2003 from the University of Oxford, by some of the
UK's foremost scientists who have taken a highly creative approach to the
problems involved in drug discovery and who have a proven record in delivering
technological excellence. The company listed on the AIM market of the London
Stock Exchange in October 2004.


Further information about the company may be accessed at the VASTox website:


www.vastox.com


This document contains "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipates", "intends", "plans",
"seeks", "believes", "estimates", "expects" and similar references to future
periods, or by the inclusion of forecasts or projections.


Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements include (factors
included in this presentation) and regional, national, global political,
economic, business, competitive, market and regulatory conditions.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAUUUACAUPQGWR
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Vox Valor Capital Charts.
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Vox Valor Capital Charts.